A 32-week, Monocentric, Exploratory, Single Arm Study to Assess Immune Function and MRI Disease Activity in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Transferred from Previous Treatment with Natalizumab to Gilenya® (Fingolimod) (ToFingo-Successor)

Basic data for this project

Type of projectOwn resources project
Duration at the University of Münster01/01/2014 - 30/06/2016

Description

KeywordsMultiple Sclerosis

Project management at the University of Münster

Faldum, Andreas

Research associates from the University of Münster

Eveslage, Maria
Urban, Marc